Effects of calcitonin therapy on osteoporosis in patients with thalassemia

Acta Haematol. 1995;93(1):20-4. doi: 10.1159/000204084.

Abstract

The aim of this study was to evaluate the effects of calcitonin (CT) treatment on bone pain, osteoporosis, bone fractures and blood chemistry in thalassemic patients. Twenty-four patients with an age range of 10-24 years were included, 14 of whom received 100 IU CT and 250 mg calcium 3 times a week. The others (n = 10) were followed up as a control group with only routine thalassemia therapy. After 1 year of treatment, bone pain disappeared and radiological signs of osteoporosis had improved significantly (p < 0.01) in the treatment group. CT has no important side effects.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bone Density
  • Calcitonin / therapeutic use*
  • Child
  • Female
  • Humans
  • Male
  • Osteoporosis / drug therapy*
  • Osteoporosis / etiology
  • Osteoporosis / physiopathology
  • Pain / drug therapy
  • beta-Thalassemia / complications*
  • beta-Thalassemia / drug therapy

Substances

  • Calcitonin